Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 219, Issue 12, Pages 1963-1968Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiz042
Keywords
HIV; inflammation; immune activation; microbiome; lactoferrin
Categories
Funding
- Hennepin Health Services (career development award)
- intramural research program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
- National Cancer Institute, NIH [HHSN261200800001E]
- intramural research program of NIAID/NIH
- NIAID microbiome core facility
- Ventria Bioscience
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001121, ZICAI001233] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Lactoferrin modulates mucosal immunity and targets mechanisms contributing to inflammation during human immunodeficiency virus disease. A randomized placebo-controlled crossover clinical trial of recombinant human (rh) lactoferrin was conducted among 54 human immunodeficiency virus-infected participants with viral suppression. Outcomes were tolerability, inflammatory, and immunologic measures, and the intestinal microbiome. The median age was 51 years, and the median CD4(+) cell count was 651/mu L. Adherence and adverse events did not differ between rh-lactoferrin and placebo. There was no significant effect on plasma interleukin-6 or D-dimer levels, nor on monocyte/T-cell activation, mucosal integrity, or intestinal microbiota diversity. Oral administration of rh-lactoferrin was safe but did not reduce inflammation and immune activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available